Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

A company presentation will take place during the conference’s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference’s Innovation track spotlights the most promising emerging ...

Oncolytic virotherapy represents an innovative and promising approach for the treatment of cancer, including multiple myeloma (MM), a currently incurable plasma cell (PC) neoplasm. Despite the ...

Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a change-up in its R&D focus. | Theriva ...

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

UroGen has issued $4m in ordinary shares to IconOVir. Credit: MacroEcon/Shutterstock. UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic ...

UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042. The company issued $4m in ordinary shares and additionally agreed ...

在抗击癌症这一人类健康的“头号杀手”之战中，武汉博威德生物技术有限公司的最新成果令人振奋。2025年2月26日，博威德生物研发的抗肿瘤创新药重组柯萨奇病毒B3注射液，商标名“爱速可”，成功获得美国食品药品监督管理局（FDA）的临床试验批准，标志着对付恶性肿瘤的治疗手段又添一把利器。

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus ...

“The acquisition of ICVB-1042, a next-generation investigational oncolytic virus, marks a significant milestone in our plan to develop novel, locally administered therapies for bladder cancer ...